NEW YORK (GenomeWeb News) – In response to Myriad Genetics' patent infringement lawsuit against Ambry Genetics, the Aliso Viejo, Calif.-based testing firm took its own legal action today by countersuing Myriad for antitrust violations.

"Myriad's lawsuit is in violation of the Sherman Antitrust Act because the asserted claims against Ambry are invalid under two [US] Supreme Court decisions and Federal Circuit authority," the company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.